Biblioteca | | Page 12

Interaction of von Willebrand factor with platelets and the vessel wall

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Interaction of von Willebrand factor with platelets and the vessel wall Archivo: tromboembolia-arterial/haemo_2015-Atherogenesis and inflammation.pdf The initiation of thrombus formation at sites of vascular injury to secure haemostasis after tissue trauma requires the interaction of surface-exposed von Willebrand factor (VWF) with its primary platelet receptor, the glycoprotein (GP) Ib-IX-V complex. As an insoluble component…

Evolución del conocimiento sobre la sangre y su movimiento. Parte II

someth1 mes desde que se envió1 mes desde que se envió04 minutos

Descarga: Evolución del conocimiento sobre la sangre y su movimiento. Parte II Archivo: historia/Composicion sangre II.pdf Conocer de que está hecha la sangre y cuáles son los beneficios que sus componentes prestan a la vida fue una interrogante que estimuló por siglos la curiosidad de los investigadores. Cada una de las épocas del saber humano…

Heparin induced thrombocytopeni

someth1 mes desde que se envió1 mes desde que se envió01 minutos

Descarga: Heparin induced thrombocytopeni Archivo: tromboembolia-venosa/tvp/haemo 2015-Heparin induced thrombocytopenia.pdf Heparin induced thrombocytopenia (HIT) is a prothrombotic syndrome initiated by platelet-activating auto-antibodies with potentially devastating complications. Once the diagnosis of HIT is suspected, discontinuation of heparin and treatment with an alternative anticoagulant are mandatory. While established drugs for HIT are no longer available, parenteral factor Xa…

Individualized antithrombotic therapy

someth1 mes desde que se envió1 mes desde que se envió05 minutos

Descarga: Individualized antithrombotic therapy Archivo: tromboembolia-venosa/haemo 2016 individualized antithrombotic therapy.pdf Clot formation in the circulation is a physiological mechanism preventing bleeding at sites of loss of vascular integrity. Clot formation may also occur intravascularly under pathological conditions, e. g. leading to myocardial infarction, stroke, and critical limb ischaemia. Clot formation involves activation of the coagulation…

Individualized antithrombotic therapy

someth1 mes desde que se envió1 mes desde que se envió05 minutos

Descarga: Individualized antithrombotic therapy Archivo: tromboembolia-venosa/haemo 2016 individualized antithrombotic therapy.pdf Clot formation in the circulation is a physiological mechanism preventing bleeding at sites of loss of vascular integrity. Clot formation may also occur intravascularly under pathological conditions, e. g. leading to myocardial infarction, stroke, and critical limb ischaemia. Clot formation involves activation of the coagulation…

Newlocations of intravascular tissue factor

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Newlocations of intravascular tissue factor Archivo: tromboembolia-venosa/tvp/haemo_2007-New locations of intravascular tissue factor .pdf Tissue factor (TF) is the major initiator of blood coagulation, and a mediator of inflammation, angiogenesis, and carcinogenesis. According to recent evidence, preformed TF and inducible expression of the protein is observed in several blood components. TF is apparently constitutively expressed…

Oral anticoagulation with edoxaban

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Oral anticoagulation with edoxaban Archivo: tromboembolia-venosa/haemo_2012-oral anticoagulation with edoxabanpdf.pdf Edoxaban (the former DU176b) an orally available direct factor Xa inhibitor has been engineered from DX-9065a, which was one of the first parenteral Xa inhibitors. Edoxaban has a time to peak plasma concentrations of 1–2 hours and a half-life of approximately 10 hours after multiple…

Biomarkers for arterial and venous thrombotic disorders

someth1 mes desde que se envió1 mes desde que se envió03 minutos

Descarga: Biomarkers for arterial and venous thrombotic disorders Archivo: tromboembolia-venosa/haemo_2014-Biomarkers for arterial and venous thrombotic disorders.pdf The haemostatic system maintains the blood in a fluid state, but allows rapid clot formation at sites of vascular injury to prevent excessive bleeding. Unbalances within the haemostatic system can lead to thrombosis. Inspite of successful research our understanding…

Biomarkers for arterial and venous thrombotic disorders

someth1 mes desde que se envió1 mes desde que se envió03 minutos

Descarga: Biomarkers for arterial and venous thrombotic disorders Archivo: tromboembolia-venosa/haemo_2014-Biomarkers for arterial and venous thrombotic disorders.pdf The haemostatic system maintains the blood in a fluid state, but allows rapid clot formation at sites of vascular injury to prevent excessive bleeding. Unbalances within the haemostatic system can lead to thrombosis. Inspite of successful research our understanding…

Comparative genetics of warfarin resistance

someth1 mes desde que se envió1 mes desde que se envió02 minutos

Descarga: Comparative genetics of warfarin resistance Archivo: tromboembolia-venosa/haemo_2014-Comparative genetics of warfarin resistance.pdf Warfarin and other 4-hydroxycoumarinbased oral anticoagulants targeting vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1) are administered to humans, mice and rats with different purposes in mind – to act as pesticides in high-dosage baits for killing rodents, but also to save lives…